With Lilly's Mounjaro set for stardom, an Alzheimer's win would be 'icing on the cake': analysts

With Eli Lilly’s latest Type 2 diabetes launch and obesity hopeful in the running to become “the biggest drug ever,” an approval for donanemab—the company’s experimental antibody effort against Alzheimer’s disease—would simply be “icing on the cake” for investors.